First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

被引：0
|
作者：
E. Van Cutsem
I. Danielewicz
M. P. Saunders
P. Pfeiffer
G. Argilés
C. Borg
R. Glynne-Jones
C. J. A. Punt
A. J. Van de Wouw
M. Fedyanin
D. Stroyakovskiy
H. Kroening
P. Garcia-Alfonso
H. Wasan
A. Falcone
R. Fougeray
A. Egorov
N. Amellal
V. Moiseyenko
机构：
[1] University Hospitals Leuven and KU Leuven,Julius Centre, University Medical Centre Utrecht
[2] Wojewodzkie Hospitals in Gdyni/Gdansk Medical University,Department of Oncology
[3] Christie Hospital NHS Foundation Trust,undefined
[4] Odense University Hospital,undefined
[5] Vall d’Hebrón Institute of Oncology and Vall d’Hebrón University Hospital,undefined
[6] University Hospital Besançon,undefined
[7] Mount Vernon Hospital,undefined
[8] Amsterdam University Medical Centres,undefined
[9] Utrecht University,undefined
[10] VieCuri Medical Centre,undefined
[11] Noord-Limburg,undefined
[12] NN Blokhin National Medical Research Centre of Oncology,undefined
[13] Moscow City Oncology Hospital N62,undefined
[14] Group Practice for Haematology and Oncology,undefined
[15] Gregorio Marañón General University Hospital,undefined
[16] Hammersmith Hospital,undefined
[17] Imperial College London,undefined
[18] University Hospital of Pisa,undefined
[19] Servier International Research Institute,undefined
[20] Saint Petersburg Scientific Practical Centre for Specialized Medical Care,undefined
来源：
British Journal of Cancer | 2022年 / 126卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1548 / 1554
页数：6
相关论文
共 50 条
  • [1] First-line trifluridine/tipiracil plus bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
    Van Cutsem, E.
    Danielewicz, I
    Saunders, M. P.
    Pfeiffer, P.
    Argiles, G.
    Borg, C.
    Glynne-Jones, R.
    Punt, C. J. A.
    Van de Wouw, A. J.
    Fedyanin, M.
    Stroyakovskiy, D.
    Kroening, H.
    Garcia-Alfonso, P.
    Wasan, H.
    Falcone, A.
    Fougeray, R.
    Egorov, A.
    Amellal, N.
    Moiseyenko, V
    BRITISH JOURNAL OF CANCER, 2022, 126 (11) : 1548 - 1554
  • [2] Phase II study evaluating trifluridine/tipiracil plus bevacizumab and capecitabine plus bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival.
    Van Cutsem, Eric
    Danielewicz, Iwona
    Saunders, Mark P.
    Pfeiffer, Per
    Argiles, Guillem
    Borg, Christophe
    Glynne-Jones, Robert
    Punt, Cornelis J. A.
    van de Wouw, Agnes J.
    Fedyanin, Mikhail
    Stroyakovskiy, Daniil
    Kroening, Hendrik
    Garcia-Alfonso, Pilar
    Wasan, Harpreet Singh
    Falcone, Alfredo
    Aubel, Paul
    Egorov, Anton
    Amellal, Nadia
    Moiseenko, Vladimir
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [3] Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
    Van Cutsem, E.
    Danielewicz, I
    Saunders, M. P.
    Pfeiffer, P.
    Argiles, G.
    Borg, C.
    Glynne-Jones, R.
    Punt, C. J. A.
    Van de Wouw, A. J.
    Fedyanin, M.
    Stroyakovskiy, D.
    Kroening, H.
    Garcia-Alfonso, P.
    Wasan, H.
    Falcone, A.
    Kanehisa, A.
    Egorov, A.
    Aubel, P.
    Amellal, N.
    Moiseenko, V
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1160 - 1168
  • [4] First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design
    Andre, Thierry
    Saunders, Mark
    Kanehisa, Akira
    Gandossi, Eric
    Fougeray, Ronan
    Amellal, Nadia Causse
    Falcone, Alfredo
    FUTURE ONCOLOGY, 2020, 16 (04) : 21 - 29
  • [5] Phase II study evaluating trifluridine/tipiracil plus bevacizumab and capecitabine plus bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis
    Lesniewski-Kmak, K.
    Moiseenko, V.
    Saunders, M.
    Wasan, H.
    Argiles, G.
    Borg, C.
    Creemers, G.
    Fedyanin, M.
    Glynne-Jones, R.
    Pfeiffer, P.
    Punt, C.
    Stroyakovskiy, D.
    Ten Tije, A.
    Van de Wouw, A.
    Kanehisa, A.
    Fougeray, R.
    Busto, N. Lopez
    Amellal, N.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 108 - 108
  • [6] QoL from TASCO1: Health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy-Results from the TASCO1 phase II study.
    Moiseyenko, Vladimir
    Saunders, Mark P.
    Wasan, Harpreet Singh
    Argiles, Guillem
    Borg, Christophe
    Creemers, Geert-Jan
    Fedyanin, Mikhail
    Glynne-Jones, Robert
    Pfeiffer, Per
    Punt, Cornelis J. A.
    Stroyakovskiy, Daniil
    Ten Tije, Albert J.
    de Wouw, Agnes W. Van
    Kanehisa, Akira
    Fougeray, Ronan
    Sabater, Javier
    Amellal, Nadia
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] Randomized study evaluating trifluridine/tipiracil (TAS-102) versus + trifluridine/tipiracil plus bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC).
    Pfeiffer, Per
    Yilmaz, Mette
    Moller, Soren
    Maltha, Line
    Krogh, Merete
    Zitnjak, Daniela
    Szameitat, Caroline Lemb
    Hejlesen, Finn
    Thomsen, Karina Gravgaard
    Qvortrup, Camilla
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [8] Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
    Kamiimabeppu, Daisaku
    Osumi, Hiroki
    Shinozaki, Eiji
    Ooki, Akira
    Wakatsuki, Takeru
    Yoshino, Koichiro
    Sato, Taro
    Nakayama, Izuma
    Ogura, Mariko
    Takahari, Daisuke
    Chin, Keisho
    Yamaguchi, Kensei
    ONCOLOGY LETTERS, 2021, 22 (05)
  • [9] Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial
    Oki, Eiji
    Makiyama, Akitaka
    Miyamoto, Yuji
    Kotaka, Masahiko
    Kawanaka, Hirofumi
    Miwa, Keisuke
    Kabashima, Akira
    Noguchi, Tomohiro
    Yuge, Kotaro
    Kashiwada, Tomomi
    Ando, Koji
    Shimokawa, Mototsugu
    Saeki, Hiroshi
    Akagi, Yoshito
    Baba, Hideo
    Maehara, Yoshihiko
    Mori, Masaki
    CANCER MEDICINE, 2021, 10 (02): : 454 - 461
  • [10] Hypertension and survival in unresectable metastatic colorectal cancer (mCRC) patients receiving first-line bevacizumab (BEV) and FOLFOX.
    Burnette, B. L.
    Grothey, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345